NCT07243691

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Sir Run Run Shaw Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study on the therapeutic effect of different infusion times on tislelizumab in high-risk postoperative hepatocellular carcinoma

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Tislelizumab: 200mg, intravenous infusion, Q3W	Postoperative adjuvant therapy (maximum of 8 cycles, each cycle lasting 21 days): \- Tislelizumab: 200 mg, intravenous infusion, Q3W. Based on previous preclinical and clinical studies on circadian rhythms and adaptive immune responses, blood samples will be collected from patients at 05:00-07:00, 11:00-13:00, 17:00-19:00, and 23:00-01:00 (every 6 hours) to analyze the subset classification of peripheral blood lymphocytes. This will help map the immune circadian rhythm and determine the optimal injection time (which will then be used as the dosing time).

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-11-01
• Completion: 2027-12-15
• First posted: 2025-11-24
• Last updated: 2025-11-24

Locations

1 site across 1 country: China